This special issue of Current Pharmaceutical Analysis focuses on the latest advancements in polypharmacology for cancer therapy. It aims to address the challenges of drug resistance and limited efficacy by exploring multi-target strategies, rational drug combinations, and AI-driven methodologies. Topics include multi-target drug design, overcoming drug resistance, synergistic drug combinations, and computational approaches. Contributions from leading researchers in the field are invited to highlight innovative solutions and future directions in this transformative area of cancer treatment.

Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance Imaging (MRI) and computed tomography (CT) scans of patients with pancreatic cysts, researchers found near-perfect accuracy when compared directly against the manual approach of chart review performed by radiologists, according to a study published in the Journal of the American College of Surgeons (JACS).

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests. Researchers will evaluate whether these blood tests will help people ages 45 to 75 find cancer early when it may be easier to treat.

Van Andel Institute scientists have developed an improved technique to comprehensively profile DNA methylation in single cells, an advance that will help researchers better study the role of epigenetics in cancer and other diseases.   

An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a new study.